I doubt that any of the big pharmas is big on playing by the Marquess of Queensbury rules either. They bribe politicians and sue whenever it serves their interests, even if it's just to harass a competitor.
To me, the best partner for OGX-011 is whoever is selling the most Taxotere since it's joined at the hip to that drug. For now, of course, that would be Sanofi, but once its patent expires and Taxotere goes generic it may very well be Teva. I'm sure that was a major reason OGXI went with Teva. They've said repeatedly that it was a competitive bid and I find that credible.